2021 Annual General Meeting of Achiko AG: Shareholders adopt all proposals

Zurich, 26 May 2021 - Achiko AG (SWX:ACHI, ISIN CH0522213468) ("Achiko" or the "Company") held its Annual General Meeting today at 10:00 CEST in Zurich. Due to the Covid-19 pandemic, this Annual General Meeting was held without physical presence of the shareholders in accordance with art. 27 para. 1 letter b Covid-19-Ordinance 3. Shareholders exercised their shareholder rights through an independent proxy.

Achiko is pleased to announce that all resolutions were duly passed. A total of 19,986,284 shareholder votes of the total share capital of CHF 1,145,592.26, divided into 114,559,226 registered shares with a nominal value of CHF 0.01 each (of which 108,903,900 are registered in the commercial register and 5,655,326 were issued from conditional capital and are not yet registered in the commercial register), were represented by the independent proxy. The board of directors would like to thank all those who exercised their rights as shareholders in this way.

The shareholders approved the annual report, including the corporate governance report, the consolidated financial statements and the statutory financial statements, as well as, in an advisory vote, the compensation report for the financial year 2020. The carry forward of the total balance sheet loss of USD (18,674,296) at year end 2020 was approved.

Allen Wu as chairman of the board of directors as well as Steven Goh and Christophe Laurent as members of the board of directors were confirmed in office for a further term of one year. The shareholders also approved all retrospective and prospective compensations of the board of directors, advisory board and executive committee for the respective compensation periods as proposed by the board of directors.

Shareholders voted to grant discharge to the members of the board of directors, executive committee as well as for all other persons involved in the management of the Company for the financial year 2020. Steven Goh as sole member and chairman of the nomination and remuneration committee, Grant Thornton AG as the auditor for the financial year 2021 and Buis Bürgi AG as independent proxy were approved as well.

"Against the backdrop of Covid-19, it has been a challenging year," said Allen Wu, Chairman of Achiko AG. "We are grateful for the patience and support of our shareholders as we transformed into a healthtech company. We are encouraged by our recent progress, including first production, and excited with the prospects of approvals through a CE mark in Europe and local approvals in Indonesia over the next few months."

About Achiko AG
Achiko creates and develops new innovations in healthcare technology through its biotechnology division, AptameX, and its sister digital mobile health technology division, Teman Sehat. The Company has created a unique telehealth capability that provides user-friendly diagnostic testing integrated with a digital passport solution for the management of Covid-19.

AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesised and widely applicable to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. The AptameX technology is licensed from Regenacellx.sl and Achiko has exclusive commercialisation rights.

Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore.

Further information can be found at www.achiko.com.

If you have any questions regarding the Company, please contact us.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Germany and Austria
Axel Mühlhaus / Dr Sönke Knop
edicto GmbH
E: achiko@edicto.de
T: +49 69 90 55 05-51

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.